Insulin-delivery device maker Valeritas (NSDQ:VLRX) missed earnings and revenue expectations on Wall Street with its 1st quarter results. The Bridgewater, N.J.-based company pared its losses to -$11.9 million on sales of $4.6 million for the 3 months ended March 31, for bottom-line growth of 30% on sales loss of -8% compared with the same period last year. […]
Diabetes
Welcome to MassDevice's Diabetes Hub, your resource for the latest news in diabetes technology. Stay informed about the innovations and business news shaping the diabetes device industry.
Here are top diabetes features from MassDevice and its sister publications (and scroll down to read the latest diabetes device news from MassDevice):
+ These diabetes devices are set to launch in 2024
+ The top IVD and diabetes tech stories of 2023
+ How Dexcom designed a new “life-changing” sensor for even more people with diabetes
+ Embecta CEO sees GLP-1 opportunities as company progresses on insulin patch pump
+ The 10 biggest diabetes tech stories from 2023
Latest Diabetes News
Senseonics, TypeZero ink development deal for artificial pancreas
Senseonics (NYSE:SENS) said yesterday that it inked a non-exclusive R&D license agreement with TypeZero Technologies to develop artificial pancreas and decision support systems for its Eversense continuous glucose monitor. The companies plan to integrate glucose readings from the Eversense system with TypeZero’s inControl artificial pancreas algorithms to regulate insulin delivery through a user’s insulin pump. […]
Researchers combine modified insulin and red blood cells to regulate blood sugar in diabetic mice
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have designed a glucose-responsive “smart” insulin delivery system using modified insulin and red blood cells. In an animal study of mice with Type I diabetes, the system effectively reduced blood sugar levels for 48 hours. The team’s work was published […]
Sanofi ties drug price increases to healthcare inflation
Insulin makers have faced questioning this year for their drug pricing practices – a class-action lawsuit filed in the U.S. District Court of Massachusetts in January alleges that Sanofi (NYSE:SNY), Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) conspired to raise their list prices to get access to pharmacy benefit managers’ preferred lists, instead of competing with each other […]
DexCom prices $350m debt offering
Dexcom Inc. (NSDQ:DXCM) yesterday priced a $350 million debt offering, adding $50 million to the private placement it expects to close May 12. The offering, of 0.75% convertible senior notes, mature in May 2022 and can be redeemed for DXCM stock in February of that year. San Diego-based DexCom said the conversion rate is about 10.1 […]
Abbott lands French reimbursement win for FreeStyle Libre glucose monitor
Abbott (NYSE:ABT) said today it won national reimbursement from the French Health ministry for its FreeStyle Libre wearable glucose monitor. The FreeStyle Libre is designed to monitor glucose through a sensor worn on the back of the upper arm for 2 weeks, without the need for the finger prick calibration required by continuous glucose monitoring […]
Novo Nordisk launches Xultophy diabetes therapy in U.S.
Novo Nordisk (NYSE:NVO) said today that it launched its Type II diabetes combination therapy, Xultophy, in pharmacies across the U.S. The injection is a combination of insulin degludec and liraglutide that is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type II diabetes. In clinical trials, Xultophy reduced […]
Nordisk shares climb after Q1 beat
Shares in Novo Nordisk (NYSE:NVO) rose today after the insulin-maker met expectations on Wall Street with its 1st quarter results. The Denmark-based company posted profits of $1.49 billion, or 60¢ per share, on sales of $4.18 billion for the 3 months ended March 31, for bottom-line growth of 7% on sales growth of 5% compared with […]
EnteroMedics, So Cal Permanente Medical ink deal for Maestro diabetes trial
EnteroMedics (NSDQ:ETRM) said last week it inked a deal with Southern California Permanente Medical Group to initiate a study investigating the use of its Maestro vBloc system for treating Type 2 diabetes patients with obesity. The Maestro device is an implantable neurostimulation device designed to intermittently block the vagus nerves using high-frequency, low-energy impulses. The therapy, which the […]
Digital health start-up Amalgam Rx launches with insulin titration app
Digital health start-up Amalgam Rx launched today with the release of iSage Rx, which it touts as the 1st FDA 510(k)-cleared, prescription mobile app for insulin titration. The app allows physicians to choose from clinically-validated basal insulin algorithms and tailor them to the needs of their patients with Type II diabetes. Patients record their blood glucose […]
Alere’s Medicare ban upheld by judge for Arriva diabetes unit
Alere (NYSE:ALR) said today that federal judge upheld a ban imposed on its Arriva Medical diabetes division by the Centers for Medicare & Medicaid Services, vowing to appeal the decision barring the unit from government insurance reimbursement. Arriva, which makes durable medical equipment for diabetic testing, was informed last October that its Medicare enrollment would be revoked by […]